The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Targeted RNA-sequencing for the quantification of MRD in AML
Quantitative PCR and flow cytometry can be utilized for the quantification of measurable residual disease (MRD), both of which have their pros and cons. Here, Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, discusses the use of targeted RNA sequencing for the quantification of MRD in acute myeloid leukemia (AML). This assay, which can be customized and expanded, is the first demonstrated use of high-sensitivity RNA sequencing for MRD detection in AML and could serve as a broadly applicable standardized tool. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
https://www.ncbi.nlm.nih.gov/pubmed/30171026
